Figure 1.

Effects of Trastuzumab-or TTF on cell viability in Trastuzumab-resistant HER2-positive human breast cancer cell. (A) TTF Inhibited Cell Proliferation in Trastuzumab-resistant HER2-positive human breast cancer cell in vitro after TTF Treatment (B) Cell viability (%) using MTT assay (C) colony forming assay. The survival fraction, which was expressed as a function of the irradiation dose, was calculated as follows: survival fraction = colonies counted/(cells seeded × plating efficiency/100). **P < 0.01, ***P < 0.001.